Late Entrant in a PMA-Only Category: Regulatory Strategy and Project Management for a Transcatheter Edge-to-Edge Valve Repair System

First-in-class devices attract most attention in regulatory strategy discussions, but a representative transcatheter edge-to-edge repair (TEER) system illustrates the more common case of a follower device: by the time a second entrant pursues US approval in an already-established therapeutic category, an incumbent has typically already shaped clinical practice patterns, reimbursement structures, and physician familiarity. This article reconstructs the generalized regulatory journey of a TEER system of this kind from classification through post-market surveillance, distinguishing documented regulatory facts from the author's own strategic analysis. The article addresses the classification rationale across three jurisdictions, the pivotal trial design choice between a single-arm and a randomized head-to-head comparison, the asymmetry between US and European Union indications for a device of this kind, and the distinct reimbursement and market-access dynamics in the United States and Canada. The article closes with recommendations for regulatory affairs professionals developing a late-entrant strategy in an established, single-pathway device category.Keywords: transcatheter edge-to-edge repair; mitral regurgitation; follower device strategy; Premarket Approval; Health Canada Class IV; EU MDR; regulatory artificial intelligence